-
「同位素标记抑制剂」CAS:1331910-75-8|Valacyclovir-d4 hydrochloride
作者:德尔塔生物 日期:2025-10-20
生物活性:Valacyclovir-d4 (hydrochloride) is the deuterium labeled Valacyclovir hydrochloride. Valacyclovir hydrochloride (Valaciclovir hydrochloride) is an orally active antiviral agent for herpes simplex, herpes zoster, and herpes B. Valacyclovir hydrochloride inhibits HSV-1 W (50=2.9 μg/ml). Valacyclovir hydrochloride is a proagent of Aciclovir (HY-17422)[1][2][3][4][5].体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.分子量:364.82Formula:C13H17D4ClN6O4CAS 号:1331910-75-8非标记 CAS:124832-27-5中文名称:盐酸伐昔洛韦 d4 (盐酸盐)运输条件:Room temperature in continental US; may vary elsewhere.储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (529 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief][2]. Valacyclovir. New indication: for genital herpes, simpler administration. Can Fam Physician. 1999 Jul;45:1698-700, 1703-5. [Content Brief][3]. Lycke J, et al. Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir. Antimicrob Agents Chemother. 2003 Aug;47(8):2438
-
「同位素标记抑制剂」CAS:1189718-34-0|Nisoldipine-d7
作者:德尔塔生物 日期:2025-10-20
生物活性:Nisoldipine-d7 (BAY-k 5552-d7) is the deuterium labeled Nisoldipine. Nisoldipine(BAY-k 5552) is a calcium channel blocker belonging to the dihydropyridines class, specific for L-type Cav1.2 with IC50 of 10 nM[1][2].体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Nisoldipine-d7 相关抗体:Annexin VI AntibodyCalbindin AntibodyCalreticulin AntibodyCatalase Antibody (YA552)Catalase Antibody (YA811)Cardiac Troponin I/TNNC1 AntibodyC Reactive Protein Antibody (YA941)SCGN Antibody (YA1167)PARK7/DJ1 Antibody (YA1799)RAMP1 Antibody (YA1818)Annexin V Antibody (YA1829)Striatin 4 Antibody (YA2088)Fibulin 5 Antibody (YA2448)RASGRP1 Antibody (YA2546)Fibulin 1 Antibody (YA2831)EFEMP1 Antibody (YA2883)CRCP Antibody (YA3350)C Reactive Protein Antibody (YA939)C Reactive Protein Antibody (YA940)Annexin VII Antibody (YA1138)Parvalbumin Antibody (YA1249)PON1 Antibody (YA1666)PON2 Antibody (YA1688)Annexin IV Antibody (YA1921)SERCA2 ATPase Antibody (YA1931)Stromal Interaction Molecule 1 Antibody (YA2092)SERCA1 ATPase Antibody (YA2157)TrpV5 Antibody (YA2284)NCX1 Antibody (YA2331)Scramblase 1 Antibody (YA2419)分子量:395.46Formula:C20H17D7N2O6CAS 号:1189718-34-0非标记 CAS:63675-72-9中文名称:尼索地平 d7运输条件:Room t
-
「同位素标记抑制剂」CAS:1219795-47-7|Nisoldipine-d4
作者:德尔塔生物 日期:2025-10-20
生物活性:Nisoldipine-d4 (BAY-k 5552-d4) is the deuterium labeled Nisoldipine. Nisoldipine(BAY-k 5552) is a calcium channel blocker belonging to the dihydropyridines class, specific for L-type Cav1.2 with IC50 of 10 nM[1][2].体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Nisoldipine-d4 相关抗体:Annexin VI AntibodyCalbindin AntibodyCalreticulin AntibodyCatalase Antibody (YA552)Catalase Antibody (YA811)Cardiac Troponin I/TNNC1 AntibodyC Reactive Protein Antibody (YA941)SCGN Antibody (YA1167)PARK7/DJ1 Antibody (YA1799)RAMP1 Antibody (YA1818)Annexin V Antibody (YA1829)Striatin 4 Antibody (YA2088)Fibulin 5 Antibody (YA2448)RASGRP1 Antibody (YA2546)Fibulin 1 Antibody (YA2831)EFEMP1 Antibody (YA2883)CRCP Antibody (YA3350)C Reactive Protein Antibody (YA939)C Reactive Protein Antibody (YA940)Annexin VII Antibody (YA1138)Parvalbumin Antibody (YA1249)PON1 Antibody (YA1666)PON2 Antibody (YA1688)Annexin IV Antibody (YA1921)SERCA2 ATPase Antibody (YA1931)Stromal Interaction Molecule 1 Antibody (YA2092)SERCA1 ATPase Antibody (YA2157)TrpV5 Antibody (YA2284)NCX1 Antibody (YA2331)Scramblase 1 Antibody (YA2419)分子量:392.44Formula:C20H20D4N2O6CAS 号:1219795-47-7非标记 CAS:63675-72-9中文名称:尼索地平 d4运输条件:Room t
-
「同位素标记抑制剂」CAS:1246820-19-8|Loxapine-d8 hydrochloride
作者:德尔塔生物 日期:2025-10-20
生物活性:Loxapine-d8 (hydrochloride) is the deuterium labeled Loxapine. Loxapine Succinate is a D2DR and D4DR inhibitor, serotonergic receptor antagonist and also a dibenzoxazepine anti-psychotic agent[1][2].体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Loxapine-d8 hydrochloride 相关抗体:MTNR1A Antibody分子量:335.86Formula:C18H11D8Cl2N3OCAS 号:1246820-19-8非标记 CAS:54810-23-0中文名称:盐酸洛沙平-d8运输条件:Room temperature in continental US; may vary elsewhere.储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (537 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief][2]. Singh AN, et al. A neurochemical basis for the antipsychotic activity of loxapine: interactions with dopamine D1, D2, D4 and serotonin 5-HT2 receptor subtypes. J Psychiatry Neurosci. 1996 Jan;21(1):29-35. [Content Brief][3]. Labuzek K, et al. Chlorpromazine and loxapine reduce interleukin-1beta and interleukin-2 release by rat mixed glial and microglial cell cultures. Eur Neuropsychopharmacol. 2005 Jan;15(1):23-30. [Content B
-
「同位素标记抑制剂」CAS:1432230-09-5|Dexpramipexole-d3 dihydrochloride
作者:德尔塔生物 日期:2025-10-20
生物活性:Dexpramipexole-d3 (dihydrochloride) is the deuterium labeled Dexpramipexole. Dexpramipexole((R)-Pramipexole), also known as R-(+)-Pramipexole, is a neuroprotective agent and weak non-ergoline dopamine agonist[1][2].IC50 & Target:D3 Receptor体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Dexpramipexole-d3 dihydrochloride 相关抗体:DRD2 AntibodyDopamine Receptor D3 Antibody (YA1742)DOPA Decarboxylase Antibody (YA2428)Dopamine Receptor D1 Antibody (YA3270)Torsin 1A Antibody (YA2935)PITX3 Antibody (YA2974)HMBS Antibody (YA3061)分子量:287.27Formula:C10H16D3Cl2N3SCAS 号:1432230-09-5非标记 CAS:104632-27-1中文名称:普拉克索杂质E-d3运输条件:Room temperature in continental US; may vary elsewhere.储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (526 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief][2]. Rudnicki SA, Berry JD, Ingersoll E, et al. Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: subgroup analysis of dem
-
「同位素标记抑制剂」CAS:1127298-67-2|Olmesartan medoxomil-d6
作者:德尔塔生物 日期:2025-10-20
生物活性:Olmesartan medoxomil-d6 (CS 866-d6) is the deuterium labeled Olmesartan medoxomil. Olmesartan medoxomil is a potent and selective angiotensin AT1 receptor inhibitor with IC50 of 66.2 μM[1][2].IC50 & Target:AT1 Receptor体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Olmesartan medoxomil-d6 相关抗体:Natriuretic Peptides A Antibody (YA1381)Angiotensinogen Antibody (YA2097)Natriuretic Peptides B Antibody (YA999)Natriuretic Peptides B Antibody (YA1000)Natriuretic Peptides B Antibody (YA1001)AGTR2 Antibody (YA3090)Angiotensin II Type 1 Receptor Antibody (YA3358)分子量:564.62Formula:C29H24D6N6O6CAS 号:1127298-67-2非标记 CAS:144689-63-4中文名称:奥美沙坦酯 d6运输条件:Room temperature in continental US; may vary elsewhere.储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (536 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief][2]. Senda A, et al. Effects of Angiotensin II Receptor Blockers on Metabolism of Arachidonic Acid via CYP2C8. Biol Pharm Bull. 2015;38(12):1975-9. [Content Brief][3]. S
-
「同位素标记抑制剂」CAS:1246818-18-7|Tolvaptan-d7
作者:德尔塔生物 日期:2025-10-20
生物活性:Tolvaptan-d7 is the deuterium labeled Tolvaptan. Tolvaptan is a selective, competitive arginine vasopressin receptor 2 antagonist with an IC50 of 1.28μM for the inhibition of AVP-induced platelet aggregation[1][2].IC50 & Target:V2 Receptor 体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.分子量:455.98Formula:C26H18D7ClN2O3CAS 号:1246818-18-7非标记 CAS:150683-30-0中文名称:托伐普坦 d7运输条件:Room temperature in continental US; may vary elsewhere.储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (536 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief][2]. Friedman B, Cirulli J.Hyponatremia in critical care patients: Frequency, outcome, characteristics, and treatment with the vasopressin V(2)-receptor antagonist tolvaptan.J Crit Care. 2012 Aug 8. [Content Brief][3]. Inomata T.Tolvaptan (vasopressin receptor antagonist).Nihon Rinsho. 2011 Nov;69 Suppl 9:408-11. [Content Brief][4]. Vaduganathan M, Gheorghiade M, Pang PS, Konstam MA, Zannad F, Swedberg K, Grinfeld L, Burnett JC Jr, Krasa H
-
「同位素标记抑制剂」CAS:1346598-10-4|Etifoxine-d5
作者:德尔塔生物 日期:2025-10-20
生物活性:Etifoxine-d5 is the deuterium labeled Etifoxine. Etifoxine, a non-benzodiazepine GABAergic compound, is a positive allosteric modulator of α1β2γ2 and α1β3γ2 subunit-containing GABAA receptors. Etifoxine reveals anxiolytic and anticonvulsant properties in rodents[1][2][3].体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Etifoxine-d5 相关抗体:GABARAP AntibodyIP3 Receptor Antibody (YA1596)GABA B Receptor 2 Antibody (YA1733)GABA B Receptor 1 Antibody (YA2418)GAD65 Antibody (YA758)GABA A Receptor alpha 1 Antibody (YA1315)GABA A Receptor beta 2 Antibody (YA1758)GABA Transporter 1 Antibody (YA1795)GAD67 Antibody (YA1807)ABAT Antibody (YA1964)GABA A Receptor alpha 5 Antibody (YA2249)GABA A Receptor beta 1 Antibody (YA2261)BGAT Antibody (YA2741)GABARAPL2 Antibody (YA2882)分子量:305.81Formula:C17H12D5ClN2OCAS 号:1346598-10-4非标记 CAS:21715-46-8中文名称:艾替伏辛-d5运输条件:Room temperature in continental US; may vary elsewhere.储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (534 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacothe
-
「同位素标记抑制剂」CAS:1246818-96-1|(rac)-Dobutamine-d6 hydrochloride
作者:德尔塔生物 日期:2025-10-20
生物活性:(rac)-Dobutamine-d6 (hydrochloride) is a labelled racemic Dobutamine hydrochloride. Dobutamine hydrochloride is a synthetic catecholamine that acts on α1-AR, β1-AR, β2-AR (α-1, β-1 andβ-2 adrenoceptors). Dobutamine hydrochloride is a selective β1-AR agonist, relatively weak activity at α1-AR and β2-AR. Dobutamine hydrochloride can increase cardiac output and correct hypoperfusion[1][2][3][4].体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.(rac)-Dobutamine-d6 hydrochloride 相关抗体:ADRB2 AntibodySalbutamol Antibody (YA901)Clenbuterol Antibody (YA904)alpha 1a Adrenergic Receptor Antibody (YA2059)分子量:343.88Formula:C18H18D6ClNO3CAS 号:1246818-96-1非标记 CAS:49745-95-1中文名称:多巴酚丁胺盐酸盐 d6 (盐酸盐)运输条件:Room temperature in continental US; may vary elsewhere.储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (530 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief][2]. Tuttle RR, et al. Dobutamine: development of a new catecholamine to selectively increase cardiac contractility.
-
「同位素标记抑制剂」CAS:1246815-74-6|(rac)-Dobutamine-d4 hydrochloride
作者:德尔塔生物 日期:2025-10-20
生物活性:(rac)-Dobutamine-d4 (hydrochloride) is a labelled racemic Dobutamine hydrochloride. Dobutamine hydrochloride is a synthetic catecholamine that acts on α1-AR, β1-AR, β2-AR (α-1, β-1 andβ-2 adrenoceptors). Dobutamine hydrochloride is a selective β1-AR agonist, relatively weak activity at α1-AR and β2-AR. Dobutamine hydrochloride can increase cardiac output and correct hypoperfusion[1][2][3][4].体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.(rac)-Dobutamine-d4 hydrochloride 相关抗体:ADRB2 AntibodySalbutamol Antibody (YA901)Clenbuterol Antibody (YA904)alpha 1a Adrenergic Receptor Antibody (YA2059)分子量:341.87Formula:C18H20D4ClNO3CAS 号:1246815-74-6非标记 CAS:49745-95-1中文名称:多巴酚丁胺盐酸盐 d4 (盐酸盐)运输条件:Room temperature in continental US; may vary elsewhere.储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (529 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief][2]. Tuttle RR, et al. Dobutamine: development of a new catecholamine to selectively increase cardiac contractility.
-
「同位素标记抑制剂」CAS:1044741-01-6|Vildagliptin-13C5,15N
作者:德尔塔生物 日期:2025-10-20
生物活性:Vildagliptin-13C5,15N (LAF237-13C5,15N; NVP-LAF 237-13C5,15N) is a 13C- and 15N-labeled Vildagliptin (HY-14291). Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity[1][2].体外研究(In Vitro):氢、碳和其他元素的稳定重同位素已被纳入药物分子中,主要作为药物开发过程中定量的示踪剂。氘化引起了人们的关注,因为它可能影响药物的药代动力学和代谢谱[1]。德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Vildagliptin-13C5,15N 相关抗体:ERK1/2 AntibodyE-Cadherin Antibody (YA470)Fatty Acid Synthase Antibody (YA766)DYKDDDDK Tag (FLAG) AntibodyGAPDH AntibodyGFP Antibodyp53 Antibody (YA250)RUNX2 AntibodyFerritin Heavy Chain AntibodyCOX2 AntibodyCtip2 AntibodyCyclin D1 Antibody (YA485)Cytochrome C Antibodyc-Myc AntibodyCyclin E1 AntibodyAIF Antibody (YA636)ALIX AntibodyCNPase AntibodyCortactin AntibodyCOX IV AntibodyCOX2/Cyclooxygenase 2 AntibodyCyclin A2 AntibodyCyclin B1 Antibody (YA486)DR5 AntibodyDrosha AntibodyE-Cadherin Antibody (YA778)EEA1 AntibodyEpCAM Antibody (YA772)Fatty Acid Synthase AntibodyFIP200 Antibody分子量:309.36Formula:C1213C5H25N215NO2CAS 号:1044741-01-6非标记 CAS:274901-16-5中文名称:维达列汀-13C5,15N;维格列汀-13C5,15N运输条件:Room temperature in continental US; may vary elsewhere.储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (539 KB)产品使用指南 (1538
-
「同位素标记抑制剂」CAS:369656-75-7|Uridine-13C,15N2
作者:德尔塔生物 日期:2025-10-20
生物活性:Uridine-13C,15N2 (β-Uridine-13C,15N2) is a 13C- and 15N-labeled Uridine (HY-B1449).体外研究(In Vitro):氢、碳和其他元素的稳定重同位素已被纳入药物分子中,主要作为药物开发过程中定量的示踪剂。氘化引起了人们的关注,因为它可能影响药物的药代动力学和代谢谱[1]。德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Uridine-13C,15N2 相关抗体:BNSP AntibodyFACL4 AntibodyBrdU Antibody (YA578)GAPDH AntibodyGlucose 6 Phosphate Dehydrogenase AntibodyMETTL3 AntibodyTSG101 AntibodyAlkaline Phosphatase AntibodyCalnexin Antibody (YA573)Lamin A/C AntibodyLamin B1 AntibodyLAMP1 AntibodyLAMP2 Antibody (YA713)LAMP2a AntibodyNQO1 Antibody (YA697)NQO1 Antibody (YA261)OPA1 AntibodyRBM3 AntibodySynaptophysin Antibody (YA043)Laminin beta 1 AntibodyHeme Oxygenase 1 AntibodyKi67 Antibody (YA717)Ki67 Antibody (YA322)Asparagine Synthetase AntibodyCalnexin AntibodyKi67 Antibody (YA001)Osteopontin AntibodySynaptophysin Antibody (YA664)TREM2 AntibodyGAPDH Antibody (YA848)分子量:247.18Formula:C813CH1215N2O6CAS 号:369656-75-7非标记 CAS:58-96-8中文名称:尿嘧啶核苷-13C,15N2运输条件:Room temperature in continental US; may vary elsewhere.储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (534 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-246. [Content Brief]
-
「同位素标记抑制剂」CAS:1185239-59-1|Muconic acid-d4
作者:德尔塔生物 日期:2025-10-20
生物活性:trans-trans-Muconic acid-d4-1 is a deuterium labeled trans-trans-Muconic acid (HY-113247). trans-trans-Muconic acid is a urinary metabolite of benzene and has been used as a biomarker of exposure to benzene in human.体外研究(In Vitro):氢、碳和其他元素的稳定重同位素已被纳入药物分子中,主要作为药物开发过程中定量的示踪剂。氘化引起了人们的关注,因为它可能影响药物的药代动力学和代谢谱[1]。德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Muconic acid-d4 相关抗体:BNSP AntibodyFACL4 AntibodyBrdU Antibody (YA578)GAPDH AntibodyGlucose 6 Phosphate Dehydrogenase AntibodyMETTL3 AntibodyTSG101 AntibodyAlkaline Phosphatase AntibodyCalnexin Antibody (YA573)Lamin A/C AntibodyLamin B1 AntibodyLAMP1 AntibodyLAMP2 Antibody (YA713)LAMP2a AntibodyNQO1 Antibody (YA697)NQO1 Antibody (YA261)OPA1 AntibodyRBM3 AntibodySynaptophysin Antibody (YA043)Laminin beta 1 AntibodyHeme Oxygenase 1 AntibodyKi67 Antibody (YA717)Ki67 Antibody (YA322)Asparagine Synthetase AntibodyCalnexin AntibodyKi67 Antibody (YA001)Osteopontin AntibodySynaptophysin Antibody (YA664)TREM2 AntibodyGAPDH Antibody (YA848)分子量:146.13Formula:C6H2D4O4CAS 号:1185239-59-1非标记 CAS:3588-17-8运输条件:Room temperature in continental US; may vary elsewhere.储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (529 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-246. [Content Brief][2]
-
「同位素标记抑制剂」CAS:1217667-10-1|Ropivacaine-d7 hydrochloride
作者:德尔塔生物 日期:2025-10-20
生物活性:Ropivacaine-d7 hydrochloride is a deuterium labeled Ropivacaine (hydrochloride) (HY-B0563B)[1]. Ropivacaine hydrochloride is a potent sodium channel blocker and blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese[2][3]. Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane[4]. Ropivacaine is widely used for neuropathic pain management in vivo[2].体外研究(In Vitro):氢、碳和其他元素的稳定重同位素已被纳入药物分子中,主要作为药物开发过程中定量的示踪剂。氘化引起了人们的关注,因为它可能影响药物的药代动力学和代谢谱[1]。德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Ropivacaine-d7 hydrochloride 相关抗体:xCT Antibody (YA006)xCT Antibody (YA652)ATP1A1 AntibodyAlpha-ENaC AntibodyLGI1 Antibody (YA2885)CRMP2 Antibody (YA3370)SLC12A1 Antibody (YA1403)CRMP1 Antibody (YA1941)Cardiac Troponin C Antibody (YA2125)CRMP5 Antibody (YA2497)CRMP3 Antibody (YA2563)Cardiac Troponin T Antibody (YA2719)SAP97 Antibody (YA2731)CRMP4 Antibody (YA2777)Kir2.1 Antibody (YA2871)分子量:317.91Formula:C17H20D7ClN2OCAS 号:1217667-10-1非标记 CAS:84057-95-4中文名称:盐酸罗哌卡因-d7运输条件:Room temperature in continental US; may vary elsewhere.储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (546 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;5
-
「同位素标记抑制剂」CAS:2982740-97-4|Pirenzepine-d8 dihydrochloride
作者:德尔塔生物 日期:2025-10-20
生物活性:Pirenzepine-d8 (LS 519-d8; Pirenzepin-d8) dihydrochloride is a deuterium labeled Pirenzepine (dihydrochloride) (HY-17037). Pirenzepine (LS 519) dihydrochloride is a selective M1 mAChR (muscarinic acetylcholine receptor) antagonist. Pirenzepine dihydrochloride reduces gastric acid secretion and reduces muscle spasm, can be used in peptic ulcers research. Pirenzepine dihydrochloride shows anti-proliferative activity to cancer cells[1][2][3].体外研究(In Vitro):氢、碳和其他元素的稳定重同位素已被纳入药物分子中,主要作为药物开发过程中定量的示踪剂。氘化引起了人们的关注,因为它可能影响药物的药代动力学和代谢谱[1]。德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Pirenzepine-d8 dihydrochloride 相关抗体:Muscarinic Acetylcholine receptor M3 AntibodyMuscarinic Acetylcholine Receptor M2 Antibody (YA2610)分子量:432.37Formula:C19H15D8Cl2N5O2CAS 号:2982740-97-4非标记 CAS:29868-97-1中文名称:二盐酸哌仑西平-d8运输条件:Room temperature in continental US; may vary elsewhere.储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (545 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-246. [Content Brief][2]. Carmine AA, et al. Pirenzepine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer disease and other allied diseases. Drugs. 1985 Aug;30(2):85-126. [Content Brief][3]. Yin QQ, et al. Mu